Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Prokidney Corp.

NASDAQ: PROK · Life Sciences · 4 alerts · CIK 1850270

Share price
$1.04Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Prokidney Corp. filings on SEC EDGAR ↗

4:18 PM ET 8-K
Financial Results

Prokidney Financial Results

ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.

Term
Q3 2026

“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”

Bruce Culleton, M.D., CEO of ProKidney
4:17 PM ET 10-Q
Financial Results

Prokidney Q3 2026 Results: Net Loss of $35.6M, Loss Widens

ProKidney Corp. reported a net loss available to Class A common stockholders of $84.1 million for the nine months ended September 30, 2026, compared to $49.8 million in the prior year period. The increase in loss was primarily driven by higher research and development expenses, which rose to $110.8 million as the company continues its clinical programs.

Key figure
Net loss $35.6M
7:01 AM ET 8-K
Investor Presentation

Prokidney Investor Presentation

ProKidney Corp. has updated its corporate investor presentation for November 2026, which management intends to use for interactions with investors and analysts. The filing also discloses that the company held $141.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, with a projected cash runway into mid-2027.

5:16 PM ET 8-K
Capital Raise

Prokidney Capital Raise

ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) offering program. Under the agreement, the company may offer and sell shares of its Class A common stock with a maximum aggregate offering price of up to $200 million. Jefferies will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds from any shares sold.

Counterparty
Jefferies LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.